Lantheus (NASDAQ:LNTH) Releases Earnings Results, Beats Estimates By $0.25 EPS

Lantheus (NASDAQ:LNTH) issued its quarterly earnings data on Thursday. The medical equipment provider reported $1.55 earnings per share for the quarter, topping analysts’ consensus estimates of $1.30 by $0.25, FiscalAI reports. The business had revenue of $388.18 million during the quarter, compared to analysts’ expectations of $363.23 million. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The company’s revenue was up 2.7% on a year-over-year basis. During the same period last year, the company posted $1.57 EPS.

Lantheus Trading Down 0.1%

Shares of LNTH stock traded down $0.12 during trading hours on Friday, hitting $100.95. 2,079,590 shares of the company were exchanged, compared to its average volume of 1,643,055. The firm has a fifty day moving average of $104.09 and a 200 day moving average of $87.98. The company has a quick ratio of 2.64, a current ratio of 3.06 and a debt-to-equity ratio of 0.43. Lantheus has a 1 year low of $49.67 and a 1 year high of $111.86. The firm has a market cap of $6.57 billion, a PE ratio of 24.38 and a beta of -0.03.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on LNTH. Truist Financial downgraded Lantheus from a “buy” rating to a “hold” rating and reduced their price objective for the company from $125.00 to $102.50 in a research report on Monday. Leerink Partners set a $102.50 target price on shares of Lantheus in a research note on Monday. CJS Securities lowered shares of Lantheus from a “market outperform” rating to a “market perform” rating in a report on Tuesday. The Goldman Sachs Group reiterated a “neutral” rating and set a $94.00 price target on shares of Lantheus in a report on Thursday, May 7th. Finally, Citizens Jmp reissued a “market outperform” rating and set a $115.00 price objective on shares of Lantheus in a research note on Monday, June 29th. Five investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Lantheus has a consensus rating of “Hold” and a consensus price target of $108.11.

Hedge Funds Weigh In On Lantheus

Several institutional investors and hedge funds have recently bought and sold shares of LNTH. Smartleaf Asset Management LLC boosted its holdings in shares of Lantheus by 63.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 197 shares during the last quarter. Osterweis Capital Management Inc. acquired a new stake in shares of Lantheus during the 2nd quarter worth $36,000. Parallel Advisors LLC raised its position in shares of Lantheus by 122.6% in the 4th quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock worth $36,000 after buying an additional 298 shares during the period. Los Angeles Capital Management LLC purchased a new position in shares of Lantheus in the 4th quarter worth $39,000. Finally, Caitong International Asset Management Co. Ltd acquired a new position in Lantheus in the third quarter valued at $55,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.